Sveva Castelli

Abstract Very high-risk neuroblastoma is induction-refractory and often harbors mutations in RAS and/or p53 signaling combined with telomere maintenance mechanisms. Event-free survival is <20% in these children. Patients unable to mobilize sufficient hematopoietic stem cells to harvest for busulfan/melphalan-based high-dose chemotherapy before autologous transplantation are also at high risk for relapse.

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

1 INTRODUCTION Seasonal rhinoconjunctivitis due to pollen allergy (SAR) affects millions of people around the globe and is particularly prevalent among children.1 Symptom-relieving drugs can control the disease, but the only disease-modifying treatment with long-term effects is an allergen-specific immunotherapy (AIT).2, 3 The efficacy of AIT depends on the precise identification of the eliciting allergen inducing IgE sensitization and triggering the patient's symptoms.4-6 Unfortunately,...